Marogna M, Massolo A, Berra D, Zanon P, Chiodini E, Canonica G W, Passalacqua G
Pneumology Unit, Cuasso al Monte, Macchi Hospital Foundation, Varese, Italy.
Allergy. 2006 Oct;61(10):1209-15. doi: 10.1111/j.1398-9995.2006.01164.x.
Numerous factors affect the evolution of respiratory allergy, in children, but little is known in adults. We assessed in a prospective study the influence of the type of allergen on the progression of disease.
Outpatients, with respiratory allergy underwent skin tests and pulmonary function/methacholine challenge at baseline and after 3 years. Patients were subdivided in pure rhinitis or rhinitis + bronchial hyperreactivity (BHR). In polysensitized subjects a single relevant allergen (mites, grasses, birch, Parietaria) was identified based on symptom distribution and when needed on nasal challenge.
6750 patients (age range 12-46) were studied. Of them, 17.8% were monosensitized but this percentage decreased to 10.4% after 3 years (P < 0.05). Subjects with pure rhinitis were 81% at the beginning and 48% at the end. After 3 years, the patients with bronchial responsiveness increased from 18% to 58% for mites, 22% to 49% for birch, 18% to 44% for grasses, 17% to 32% for Parietaria, with a significant difference among allergens (P < 0.05). Almost the same was seen in monosensitized subjects, being mites most likely to cause a worsening. All patients with BHR at baseline received immunotherapy. In these patients the onset of new sensitizations was significantly lower than in the group (pure rhinitis) receiving drugs only and lower airways symptoms disappeared more frequently.
The different type of allergen influences the course of the disease, as well as the use of immunotherapy.
许多因素影响儿童呼吸道过敏的演变,但成人方面了解甚少。我们在一项前瞻性研究中评估了过敏原类型对疾病进展的影响。
患有呼吸道过敏的门诊患者在基线时和3年后接受皮肤试验以及肺功能/乙酰甲胆碱激发试验。患者被分为单纯鼻炎组或鼻炎 + 支气管高反应性(BHR)组。在多敏患者中,根据症状分布并在必要时通过鼻激发试验确定单一相关过敏原(螨虫、草、桦树、墙草)。
共研究了6750例患者(年龄范围12 - 46岁)。其中,17.8%为单敏,但3年后该比例降至10.4%(P < 0.05)。单纯鼻炎患者开始时占81%,结束时占48%。3年后,螨虫导致支气管反应性的患者从18%增至58%,桦树从22%增至49%,草从18%增至44%,墙草从17%增至32%,过敏原之间存在显著差异(P < 0.05)。单敏患者情况大致相同,螨虫最易导致病情恶化。所有基线时患有BHR的患者均接受免疫治疗。在这些患者中,新致敏的发生率显著低于仅接受药物治疗的组(单纯鼻炎组),下呼吸道症状更频繁消失。
不同类型的过敏原影响疾病进程以及免疫治疗的应用。